SNSidra Naz

Sidra Naz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sidra Naz has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Procedural safety of transcatheter aortic valve replacement with Portico valve: a systematic review

    by Vikash Jaiswal, Zarghoona Wajid, Vinay Suresh, Muhammed Hanif, Kripa Rajak, Anupam Halder, Evbayekha Endurance, Henry Aiwuyo, Jinal Choudhari, Sidra Naz, et al.

    Background: The Portico transcatheter aortic heart valve is a self-expandable, fully resheathable bioprosthetic valve with a nitinol frame and porcine pericardial sealing cuff. It has been used among symptomatic severe aortic stenosis (AS) who are at high or extreme surgical risk. However, till date very few studies has been reported with inconclusive evidence for its postprocedure safety outcomes. Objective: The authors aim to evaluate the safety of the Portico transcatheter aortic valve replacement system among patients with AS. Methodology: The authors conducted a systematic literature search on PubMed, Embase, and Scopus from inception till 10th April 2023 by using predefined MESH terms using ‘AND’ and ‘OR’. The following search terms were used: ‘Aortic Stenosis’ AND ‘Transcatheter aortic valve replacement’ OR ‘Portico valve’. Finally, descriptive statistics were used to summarize the data in this paper. The mean and SD were adopted to describe continuous variables, whereas frequencies and percentages were used for dichotomous data. Results: A total of 7 studies with 2782 patients were included in the analysis. The mean age of patients was 82.3 years, and 54.63% were female. The most common comorbidity was hypertension (65.21%) and diabetes mellitus (26.45%). Among patients of AS with Portico valve implants, postprocedural outcomes including 30-day mortality (2.32%), cardiovascular mortality (2.37%), stroke (2.23%), myocardial infarction (0.94%), major bleeding (3.97%), major vascular complications (4.91%), acute kidney injury (1.37%), and permanent pacemaker implantations in 15.73% patients were reported. Overall, device success was observed in 95.82% of patients. Conclusion: Transcatheter aortic valve replacement with the repositionable Portico valve, a new bioprosthesis, appears to have a low postprocedural mortality rate and other clinical outcomes in high-risk patients with severe AS.


  • Open Access

    Percutaneous coronary intervention versus coronary artery bypass grafting among patients with left ventricular systolic dysfunction: a systematic review and meta-analysis

    by Vikash Jaiswal, Song Peng Ang, Abhigan Babu Mbbs Shrestha, Amey Mbbs Joshi, Angela Ishak, Jia Ee Mbbs Chia, Sanchita Suresh Mbbs Kanakannavr, Sidra Naz, Neel Mbbs Doshi, Dhairya Nanavaty, et al.

    Background: Current guidelines have shown the superiority of coronary artery bypass grafting (CABG) over medical therapy. However, there is a paucity of data evaluating the optimal revascularization strategy in patients with ischemic left ventricular systolic dysfunction (LVSD). Objective: The authors aimed to evaluate the clinical outcomes of postpercutaneous coronary intervention (PCI) and CABG among patients with LVSD. Methods: The authors performed a systematic literature search using the PubMed, Embase, Scopus, and the Cochrane Libraries for relevant articles from inception until 30 November 2022. Outcomes were reported as pooled odds ratio (OR), and their corresponding 95% CI using STATA (version 17.0, StataCorp). Results: A total of 10 studies with 13 324 patients were included in the analysis. The mean age of patients in PCI was 65.3 years, and 64.1 years in the CABG group. The most common comorbidities included: HTN (80 vs. 78%) and DM (49.2 vs. 49%). The mean follow-up duration was 3.75 years. Compared with CABG, the PCI group had higher odds of all-cause mortality (OR 1.15, 95% CI 1.01–1.31, P=0.03), repeat revascularization (OR 3.57, 95% CI 2.56–4.97, PP=0.048) while the incidence of cardiovascular mortality (OR 1.23, 95% CI 0.98–1.55, P=0.07), stroke (OR 0.73 95% CI: 0.51–1.04, P=0.08), major adverse cardiovascular and cerebrovascular events (OR 1.36, 95% CI 0.99–1.87, P=0.06), and ventricular tachycardia (OR 0.79, 95% CI 0.22–2.86, P=0.72) was comparable between both the procedures. Conclusion: The results of this meta-analysis suggest that CABG is superior to PCI for patients with LVSD. CABG was associated with a lower risk of all-cause mortality, repeat revascularization, and incidence of myocardial infarction compared with PCI in patients with LVSD.